Keloid scarring is an abnormal healing response characterised by excessive localised growth of scar tissue in response to skin trauma, burns or infection (Seifert 2009). It is generally considered to be distinct from hypertrophic scarring, another type of abnormal scar, in that it grows outside the boundaries of the original wound and does not regress over time, as well as having microscopic differences in structure (McGrouther 1994). The cause of keloid scarring is unknown but there is a genetic predisposition in individuals with darker skin types and an incidence of 16% in those from black and Hispanic backgrounds (Chike-Obi 2009). The lesions appear more commonly in specific body locations such as the ears, face, chest and shoulders, have a greater prevalence in people aged between 10 to 30 years old and are reported to occur in 5% to 15% of all wounds (Bayat 2003; Berman 1995). Although not malignant, keloids can often cause symptoms such as pain and itching and are frequently unsightly, potentially resulting in significant social and psychological distress 1 5-Fluorouracil for keloid scars (Protocol)